Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience | |
Liu, Tongxin1,2,3,4; Sun, Quanquan1,3,4; Qin, Weifeng1,2,3,4; Chen, Xiaozhong1,2,3,4; Hu, Qiaoying1,2,3,4 | |
刊名 | CANCER MANAGEMENT AND RESEARCH |
2020 | |
卷号 | 12 |
关键词 | olfactory neuroblastoma neoadjuvant chemotherapy precise radiotherapy |
ISSN号 | 1179-1322 |
DOI | 10.2147/CMAR.S259921 |
通讯作者 | Hu, Qiaoying(huqy316@hotmail.com) |
英文摘要 | Purpose: Esthesioneuroblastoma (ENB) is a type of rare malignant neoplasm of the sinonasal cavity. Optimal treatment for ENB is still controversial. A retrospective study was conducted to identify the clinical outcome and optimal treatment for ENB in the era of intensity-modulated radiation therapy (IMRT). Patients and Methods: Between December 2006 and August 2018, 37 patients with ENB without distant metastasis who underwent neoadjuvant chemotherapy followed by chemoradiotherapy (C+RC) or surgery followed by radiotherapy or chemoradiotherapy (S+R/RC) were retrospectively reviewed at our center. Results: The median follow-up period was 63.7 months (range, 13.2-111.5 months). Five-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) were similar between treatment arms (P values > 0.05). With a multivariate analysis, a Karnofsky Performance Status (KPS) of <= 80 was a prognostic factor for poor five-year OS. A KPS of <= 80 and Kadish class C-D tumors were prognostic factors for poor PFS. A KPS of <= 80 was a prognostic factor for poor LRFS. When KPS was <= 80 and tumors were Kadish class C-D, T3-4 and Ni were prognostic factors for poor DMFS. Subgroup analyses also demonstrated that the two treatment arms exhibited similar trends for OS, PFS, LRFS, and DMFS, excluding patients with Ni or Kadish class A-B tumors (P values > 0.05). Conclusion: In the era of IMRT, S+R/RC failed to improve the outcomes of patients with ENB. C+RC may be a feasible treatment option for patients with ENB. |
资助项目 | National Natural Science Foundation of China[81502647] ; National Natural Science Foundation of China[81502646] ; Zhejiang Medical and Health Science and Technology Project[2016KYB042] ; Zhejiang Medical and Health Science and Technology Project[2018KY298] |
WOS关键词 | OLFACTORY NEUROBLASTOMA ; ADJUVANT CHEMOTHERAPY ; RESECTION ; CARCINOMA ; UTILITY |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | DOVE MEDICAL PRESS LTD |
WOS记录号 | WOS:000571902200001 |
资助机构 | National Natural Science Foundation of China ; Zhejiang Medical and Health Science and Technology Project |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/104260] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Hu, Qiaoying |
作者单位 | 1.Key Lab Radiat Oncol Zhejiang Prov, Hangzhou 310022, Zhejiang, Peoples R China 2.Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Hangzhou 310022, Zhejiang, Peoples R China 3.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Zhejiang, Peoples R China |
推荐引用方式 GB/T 7714 | Liu, Tongxin,Sun, Quanquan,Qin, Weifeng,et al. Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience[J]. CANCER MANAGEMENT AND RESEARCH,2020,12. |
APA | Liu, Tongxin,Sun, Quanquan,Qin, Weifeng,Chen, Xiaozhong,&Hu, Qiaoying.(2020).Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience.CANCER MANAGEMENT AND RESEARCH,12. |
MLA | Liu, Tongxin,et al."Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience".CANCER MANAGEMENT AND RESEARCH 12(2020). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论